Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Closer Look: Why Are Indian Pharma Promoters Diversifying Into Other Sectors?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Earlier this month when Piramal Healthcare Ltd.'s Chairman Ajay Piramal announced a foray into the financial services sector, local pharma watchers were reminded of the much-touted "game-changing" deal that the scion of Ranbaxy Laboratories Ltd. Malvinder Singh struck with Daiichi Sankyo three years ago
Advertisement

Related Content

Indian Firms Need To Change Management Style, Focus On Innovation To Grow, Say Execs
Analysts Question Sun Pharma’s Future Investment Plans As Former CFO Invests In Telenor
Lupin Categorically Denies Sell-off Talks Amid Speculation Of $1 Billion Valuation For India Business
Lupin Categorically Denies Sell-off Talks Amid Speculation Of $1 Billion Valuation For India Business
Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma
Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma
On Heels Of Emerging Markets Deal, Merck Ropes In India's Sun Pharma To Boost Januvia Sales
Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs
Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs
Advertisement
UsernamePublicRestriction

Register

SC077955

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel